In the PARAGON-HF trial, the 193 patients (4.0%) who did not meet the final natriuretic peptide-based inclusion criteria (NT-proBNP > 300 ng/L for patients in sinus rhythm or >900 ng/L for those in atrial fibrillation/flutter) showed a lower rate of HF hospitalizations and cardiovascular death compared to those who did meet the criteria [73]. Here, NPPB is linked to atrial fibrillation.